At CR2O, we understand the importance of timing, experience and flexibility for the successful execution of a vaccine study. Our track record spans both preventive and therapeutic vaccines, subunit and conjugates across all phases I-IV in more than 15 countries, 190 study centers and 2500 patients.
Prof. Dr. Ab Osterhaus is a world renowned virologist. He is also a founding father of CR2O and acts as Chief Scientific Officer. He firmly believes that through CR2O, we can accelerate development of intervention strategies for human infectious diseases.
We have successfully supported more than 100 oncology studies, covering a wide range of indications within this therapeutic area. This makes oncology and oncologic studies our core expertise and focus.
Our experience can add value to your study by providing access to key investigators, experienced study centers, networks of specialized labs, insightful study design and much more.
We are proud that the distinguished cancer physician-scientist Prof. Dr. Herbert (Bob) Pinedo joined CR2O as Scientific Advisor. Prof. Pinedo is unquestionably a top-class scientist of international renown. The main focus of his work concerns the mode of action of anti-cancer drugs.
Despite a wide range of available standard of care treatments, biologic therapies and employment of combination with synthetic disease modifying anti-rheumatic drug strategies there remains a significant unmet medical and societal need for new, clinically efficacious therapies which are safe and affordable for rheumatism.
Our significant rheumatology track record in managing large investigator initiated trials (incl. Horizon2020), registry trials and industry sponsored clinical trials saves you valuable time and budget, allowing you to focus on what you do best.
CR2O houses several ambitious PhD candidates with particular interest in intestinal microbiota, and its role in maintaining health throughout life.
Fermented foods have played an indispensable role in ancient cultures and have been widely acknowledged across continents. But it was not until the early 1900s, that Elie Metchnikoff first theorized that host-friendly bacteria found in yogurt could promote health through manipulation of the intestinal microbiome (Metchnikoff, 1908). These microorganisms are known today as probiotics and fuel a multi-billion-dollar industry (Global Market Insights, 2016). We strive strengthening scientific evidence to prove a cause and effect relationship between consumption of probiotic products and health benefits.
MEET OUR PROBIOTICS TEAM:
JOOST FLACH, MSc.
Joost performed extensive market analysis in the field of clinical human challenge studies. He focusses on design and conduct of innovative human challenge studies and functional food research.
PAMELA BROWNE, MD
One of Pamela’s clinical trials focuses on the relation between prenatal maternal stress and child health outcomes, with maternal and infant microbiota as a possible mediating mechanism in this relation. Other clinical trials involve testing efficacy of probiotics in constipation in elderly, and in collaboration with AMC Amsterdam, she investigates the effectiveness of hypnotherapy on functional nausea in children. Pamela is currently also working on an academic book on infant and child microbiota in relation to health.
MARK VAN DER WAAL
Mark’s research primarily concentrates on the field of medical nutrition in which he performs clinical efficacy-related studies. Additionally, his doctoral research aims to develop further understanding of the key drivers of organisational value creation, taking a special interest in the role of intellectual capital and intellectual property rights in processes of innovation.